<DOC>
	<DOCNO>NCT02152423</DOCNO>
	<brief_summary>Because anti-Xa ease administration activity , Low molecular weight heparin represent attractive alternative unfractionated heparin . Several clinical trial demonstrate Low molecular weight heparin effective Unfractionated heparin without increase bleed complication . Enoxaparin study . Its use recommend . Demonstrate Enoxamed® comparable Lovenox® anti-Xa activity action .</brief_summary>
	<brief_title>Enoxamed Study Treatment Acute Coronary Syndromes</brief_title>
	<detailed_description>Single-center randomize control trial , single-blind , include patient acute coronary syndrome confirm , measure anti-Xa activity H0 H4.the study do two group ; ENOXAMED® group : In case patient receive injection enoxaparin ( ENOXAMED® ; Unimed Laboratories ) intravenously . Curative dose ( 100 IU/10 kg ) . Control group ( LOVENOX ® ) In case patient receive LOVENOX intravenous injection curative dose 100 kg IU/10 .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Enoxaparin</mesh_term>
	<criteria>Age 18 year old With acute coronary syndrome confirm Age le 18 year Persistent ST segment elevation Contre indication enoxaparin heparin general . Patient participate another study , Pregnant nursing woman patient take anticoagulant last three month , Patients coagulopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>enoxaparin</keyword>
	<keyword>Enoxamed</keyword>
	<keyword>lovenox</keyword>
	<keyword>anti Xa</keyword>
	<keyword>acute coronary syndrome</keyword>
</DOC>